Friday, April 16, 2021 6:44:57 PM
Less well known than competing coronavirus vaccines from Pfizer or Moderna, Singh notes that INO-4800 has several advantages to recommend it. For one, it’s DNA-based, and thus can theoretically be modified to combat mutated versions of the COVID-19 coronavirus. For another, it offers a better “safety/tolerability profile,” that could recommend it as an alternative to other vaccines. And for a third, INO-4800 is said to be both easier to store and has a longer shelf life than other vaccines on the market today, which might make it more suitable for stockpiling against future coronavirus outbreaks.
VGX-3100 is the next most valuable of Inovio’s vaccine candidates, thinks Singh, being worth perhaps $7 a share. It’s also, says the analyst, the vaccine with the “highest sustainability and potential upside on commercialization” for Inovio, as HPV will presumably remain a problem long after the coronavirus pandemic has gone away. Singh also sees “potential to expand into other (pre)cancerous indications” based on research done for VGX-3100.
Finally, Singh sees INO-5401 as worth perhaps $5 a share to Inovio stock. In the analyst’s view, INO-5401 could be a “potential breakthrough” drug for treating patients with glioblastoma, a cancer that has not seen a real improvement in treatment options “for decades.”
Other vaccine candidates in the pipeline, plus Inovio’s cash on hand, make up the final $3 of the analyst’s target valuation for Inovio.
Not all this value may be immediately apparent to investors, however. Notably, Singh admits that revenues at Inovio over the past three years have been measured in the low single digits of millions of dollars. It won’t be until next year, says the analyst before sales really grow appreciably. But once these vaccines begin coming to market, the analyst sees significant growth potential: $656 million in sales in 2022, twice that in 2023, $2.1 billion in 2024, and $3 billion in 2025.
Profits will only emerge alongside sales next year — $1.46 per share.
Indeed, by 2025, the analyst forecasts that Inovio could be earning $6.48 per share, per year, making today’s price target of $35 (not to mention today’s actual share price of $15) look cheap indeed. And indeed, that’s probably why the analyst is rating the stock “outperform” and recommending that investors buy it.
Recent INO News
- INOVIO Reports Inducement Grants Under Inducement Plan • PR Newswire (US) • 05/01/2024 12:00:00 PM
- INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024 • PR Newswire (US) • 04/29/2024 12:00:00 PM
- INOVIO to Participate in Upcoming Investor Conferences in May • PR Newswire (US) • 04/29/2024 12:00:00 PM
- INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants • PR Newswire (US) • 04/15/2024 10:39:00 PM
- INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine • PR Newswire (US) • 03/26/2024 10:28:00 PM
- INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights • PR Newswire (US) • 03/06/2024 09:05:00 PM
- Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting • PR Newswire (US) • 03/06/2024 12:00:00 PM
- U.S. Stock Futures Gain Ahead of Economic Insights; Oil Prices Climb • IH Market News • 03/06/2024 11:02:03 AM
- INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024 • PR Newswire (US) • 02/21/2024 01:00:00 PM
- INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • PR Newswire (US) • 02/07/2024 04:46:00 PM
- INOVIO Reports Inducement Grant Under Inducement Plan • PR Newswire (US) • 02/02/2024 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/01/2024 05:15:24 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:01:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:02:31 PM
- INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split • PR Newswire (US) • 01/23/2024 01:00:00 PM
- INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader • PR Newswire (US) • 01/22/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2024 10:27:59 PM
- INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi) • PR Newswire (US) • 01/04/2024 01:00:00 PM
- INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program • PR Newswire (US) • 01/03/2024 01:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2023 09:05:57 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/17/2023 09:00:28 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/09/2023 09:35:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:15:59 PM
- INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights • PR Newswire (US) • 11/09/2023 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:00:10 PM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM